Researchers found that in mouse models (in a lab), SARS‑CoV‑2 mRNA vaccination triggered strong type I interferon signals, ...

Takeda and Protagonist Therapeutics have submitted a new drug application to the FDA for rusfertide for adults with ...

Children conceived through assisted reproductive technology (ART) were modestly more likely to develop asthma, allergic ...

A new drug application (NDA) has been submitted to the FDA seeking approval of rusfertide, an investigational hepcidin ...

Takeda & Protagonist submit NDA to US FDA seeking approval for rusfertide to treat polycythemia vera: Osaka, Japan Wednesday, January 7, 2026, 17:00 Hrs [IST] Takeda, focused on c ...

This study shows that SARS-CoV-2 infection and vaccination generate strong, highly specific spike-binding immune responses ...

Here are the most-read “5 things” articles from 2025.

Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics ("Protagonist") announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of ...

Real-time index price for S&P 500 Financials [Sector] (SRFI), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

When a person suffers a stroke, physicians must restore blood flow to the brain as quickly as possible to save their life.

The FDA approved Scinopharm's glatiramer acetate injection, a generic version of Copaxone, to treat multiple sclerosis.

Senate Bill 11 was introduced as lethal injection drugs have become more expensive and hard to get, leading some states to ...